Carsgen's First Enrolled Subject In The THANK-U Plustm Platform-Based Allogeneic CAR-T Trial Achieves Scr At Week 4
CARsgen Therapeutics Holdings Limited (Stock Code: 2171), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the first ...